TNSN01041A1 - Composition comprenant une dispersion solide amorphe d'un inhibiteur de glycogene-phosphorylase, et procede pour sa preparation - Google Patents

Composition comprenant une dispersion solide amorphe d'un inhibiteur de glycogene-phosphorylase, et procede pour sa preparation

Info

Publication number
TNSN01041A1
TNSN01041A1 TNTNSN01041A TNSN01041A TNSN01041A1 TN SN01041 A1 TNSN01041 A1 TN SN01041A1 TN TNSN01041 A TNTNSN01041 A TN TNSN01041A TN SN01041 A TNSN01041 A TN SN01041A TN SN01041 A1 TNSN01041 A1 TN SN01041A1
Authority
TN
Tunisia
Prior art keywords
preparation
solid dispersion
amorphous solid
glycogene
composition
Prior art date
Application number
TNTNSN01041A
Other languages
English (en)
Inventor
C Babcock Walter
Thomas Friesen Dwayne
Alan Lorenz Douglas
Macri Chris
Alan Schriver Nightingale James
Mysore Shanker Ravi
Caspar Hancock Bruno
D Crew Marshall
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01041A1 publication Critical patent/TNSN01041A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L’INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE DISPERSION SOLIDE AMORPHE DE 1[(S)-BENZYL – (2R)- HYDROXY –3- (3R,4S)-DIHYDROXY-PYRROLIDINE –1-YL-)-3-OXYPROPYL] AMIDE D’ACIDE 5- CHLORO-1H-INDOLE-2- CARBOXYLIQUE DANS UN POLYMERE D’AUGMENTATION DE CONCENTRATION. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION ET DES FORMES POSOLOGIQUES LES CONTENANT. APPLICATION : UTILISATION POUR LA SUPPRESSION DE LA PRODUCTION DE GLUCOSE HEPATIQUE.
TNTNSN01041A 2000-03-16 2001-03-15 Composition comprenant une dispersion solide amorphe d'un inhibiteur de glycogene-phosphorylase, et procede pour sa preparation TNSN01041A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19012500P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
TNSN01041A1 true TNSN01041A1 (fr) 2005-11-10

Family

ID=22700102

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01041A TNSN01041A1 (fr) 2000-03-16 2001-03-15 Composition comprenant une dispersion solide amorphe d'un inhibiteur de glycogene-phosphorylase, et procede pour sa preparation

Country Status (16)

Country Link
US (2) US20010053791A1 (fr)
EP (1) EP1263433A2 (fr)
JP (2) JP2003526666A (fr)
AR (2) AR028253A1 (fr)
AU (1) AU2001240978A1 (fr)
CA (1) CA2403233A1 (fr)
CO (1) CO5271644A1 (fr)
GT (1) GT200100039A (fr)
MX (1) MXPA02009098A (fr)
PA (1) PA8513701A1 (fr)
PE (1) PE20011268A1 (fr)
SV (1) SV2002000342A (fr)
TN (1) TNSN01041A1 (fr)
TW (1) TW200304377A (fr)
UY (1) UY26615A1 (fr)
WO (1) WO2001068092A2 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
DE60233874D1 (de) 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
WO2003000226A2 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
CN1259909C (zh) * 2002-01-16 2006-06-21 兴和株式会社 含有2,2－二氯－12－(4－氯苯基)－十二烷酸的药物组合物
WO2003063822A2 (fr) 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
EP1469829B1 (fr) * 2002-02-01 2016-01-27 Bend Research, Inc Formes posologiques a liberation immediate, contenant des dispersions medicamenteuses solides
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CA2474958A1 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1523471B1 (fr) * 2002-07-11 2009-09-16 Sanofi-Aventis Deutschland GmbH Acylurees substituees par uree et urethane, procedes permettant de les produire et leur utilisation comme medicaments
BR0313428A (pt) * 2002-08-12 2005-06-28 Pfizer Prod Inc Composições farmacêuticas de drogas semi-ordenados e polìmeros
EP2301526B1 (fr) 2003-03-26 2016-03-23 Egalet Ltd. Système de libération contrôlée de morphine
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
US20110027357A1 (en) * 2004-02-18 2011-02-03 Isaac Gilinski Compositions and methods for timed release of water-soluble nutritional supplements
US8158138B1 (en) 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
EP1753402B1 (fr) * 2004-05-28 2008-10-01 Pfizer Products Incorporated Compositions pharmaceutiques aux performances accrues comprenant un polymère hpmca
TWI389688B (zh) * 2004-06-08 2013-03-21 Vertex Pharma Vx-950之形態與調配物及其製備方法與用途
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
CA2594694A1 (fr) 2005-01-28 2006-08-03 Pfizer Products Inc. Deshydratation de particules contenant un medicament
EP2548894A1 (fr) * 2005-02-03 2013-01-23 Bend Research, Inc. Compositions pharmaceutiques à éfficacité améliorée
JP2008534522A (ja) * 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
WO2007056205A2 (fr) * 2005-11-04 2007-05-18 Eastman Chemical Company Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
TW201414469A (zh) 2006-03-20 2014-04-16 Vertex Pharma 對包括ｖｘ-９５０之藥物實施噴霧乾燥之方法及由此方法製備之產物
EP2090298A4 (fr) * 2006-11-13 2014-02-26 Kyorin Seiyaku Kk Procédé de production d'un comprimé à libération prolongée
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
EP1938804A1 (fr) * 2006-12-22 2008-07-02 Novartis AG Préparation pharmaceutique comprenant un antagoniste de neurokinine
CA2930487A1 (fr) * 2007-01-16 2008-07-24 Egalet Ltd. Utilisation (i) d'un polyglycol et (ii) d'une substance medicamenteuse active dans la preparation d'une composition pharmaceutique destinee (i) a reduire le risque de liberation massive induite par l'alcool et/ou (ii) a reduire le risque de toxicomanie medicamenteuse
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA3076115C (fr) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
EP4008314A3 (fr) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Mélange thermocinétique pour applications pharmaceutiques
US8518381B2 (en) 2008-03-28 2013-08-27 The Procter & Gamble Company Processes of making oral compositions containing gel networks
WO2009129301A2 (fr) * 2008-04-15 2009-10-22 Schering Corporation Compositions pharmaceutiques orales dans une dispersion solide moléculaire
BRPI0910627A2 (pt) * 2008-04-15 2015-09-22 Schering Corp composições de alta densidade contendo posaconazol e formulações compreendendo as mesmas
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
CA2751834C (fr) 2009-02-13 2018-07-24 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabetique et ses utilisations
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
JP5757681B2 (ja) * 2009-08-12 2015-07-29 富士フイルム株式会社 セルロース誘導体、樹脂組成物、成形体及びその製造方法並びに電気電子機器用筐体
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
EP2389934A1 (fr) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prégabaline en comprimé à libération prolongée
MY171941A (en) 2010-11-24 2019-11-08 Melinta Subsidiary Corp Pharmaceutical compositions
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013169523A1 (fr) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Compositions à solubilité augmentée
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
WO2014042945A1 (fr) * 2012-09-11 2014-03-20 Bend Research, Inc. Procédés de fabrication de formes posologiques solides pharmaceutiques de dispersion séchées par pulvérisation
EP2964243B1 (fr) 2013-03-06 2022-11-23 Capsugel Belgium NV Particules lipidiques solides de curcumine et procédés de préparation et utilisation
EP3102188A4 (fr) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Nouveaux systèmes de désintégration de formes dosifiées pharmaceutiques
US20180000738A1 (en) * 2014-10-23 2018-01-04 Bend Research, Inc. Novel spray nozzle and process for making nanoparticles
EP3212169B1 (fr) 2014-10-31 2021-01-13 Bend Research, Inc. Procédé de formation de domaines actifs dispersés dans une matrice
WO2016087261A1 (fr) 2014-12-04 2016-06-09 Capsugel Belgium N.V. Formulations multiparticulaires lipidiques
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US20190381025A1 (en) * 2017-01-20 2019-12-19 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2021076920A1 (fr) 2019-10-16 2021-04-22 Capsugel Belgium Nv Procédé et composition pour augmenter la synthèse de protéines musculaires
JP2023506222A (ja) 2019-12-10 2023-02-15 カプスゲル・ベルジャン・ナムローゼ・フェンノートシャップ 脂質マトリックスコアおよび活性成分を含有する粒子
EP4262805A1 (fr) * 2020-12-16 2023-10-25 Merck Sharp & Dohme LLC Forme posologique en mini-comprimé d'un inhibiteur de terminase virale et ses utilisations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31547A (en) * 1861-02-26 Improvement in polishing iron bars and rods
US27614A (en) * 1860-03-27 Improvement in cultivators
US3146A (en) * 1843-06-24 Improvement in friction-matches
ES2061623T3 (es) 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
ATE108996T1 (de) 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
JP3155028B2 (ja) 1991-06-10 2001-04-09 大川原化工機株式会社 噴霧乾燥造粒装置
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4220782A1 (de) 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3585654B2 (ja) 1996-07-11 2004-11-04 株式会社パウダリングジャパン ２段乾燥式スプレードライヤー装置
CN1222317C (zh) 1996-07-12 2005-10-12 第一制药株式会社 可迅速崩解的压模物质及其生产方法
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
JP2000072676A (ja) 1998-09-01 2000-03-07 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
EP1027886B1 (fr) 1999-02-10 2008-07-09 Pfizer Products Inc. Dispersions pharmaceutiques solides
EP1027888B1 (fr) 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
US6296149B1 (en) 1999-04-16 2001-10-02 Depuy Orthopaedics, Inc. Monomer delivery device for bone cement delivery system
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
CN1402632A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 水凝胶驱动的药物剂型
EP1712222A3 (fr) * 1999-12-23 2012-06-20 Pfizer Products Inc. Compositions pharmaceutiques fournissant des concentrations de médicaments améliorées
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
AR040281A2 (es) 2005-03-23
AU2001240978A1 (en) 2001-09-24
WO2001068092A2 (fr) 2001-09-20
CO5271644A1 (es) 2003-04-30
WO2001068092A3 (fr) 2002-03-21
PE20011268A1 (es) 2001-12-12
JP2003526666A (ja) 2003-09-09
GT200100039A (es) 2001-12-31
SV2002000342A (es) 2002-07-16
UY26615A1 (es) 2001-10-25
AR028253A1 (es) 2003-04-30
EP1263433A2 (fr) 2002-12-11
TW200304377A (en) 2003-10-01
PA8513701A1 (es) 2002-10-24
MXPA02009098A (es) 2003-03-12
US20010053791A1 (en) 2001-12-20
US20030185891A1 (en) 2003-10-02
US7235260B2 (en) 2007-06-26
JP2007182449A (ja) 2007-07-19
CA2403233A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
TNSN01041A1 (fr) Composition comprenant une dispersion solide amorphe d'un inhibiteur de glycogene-phosphorylase, et procede pour sa preparation
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
TNSN01167A1 (fr) Formes de sels d'amide d'acide 3-(4-bromo-2,6-difluoro-benzyloxy) - 5 [3 - (4 - pyrrolidine - 1 - yl - butyl) ureido] isothiazole - 4 - carboxylique, et procede pour leur production.
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00252A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26551A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
TNSN01009A1 (fr) (+) - 6 - [amino - (6 - chloro - pyridine - 3 - yl) - (3 - methyl - 3h - imidazole - 4 - yl) - methyl ] - 4 - ( 3 - chloro-phenyl) -1- cyclopropylmethyl - 1h - quinoleine - 2 - one, procede pour sa preparation et composition la contenant
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
MA29554B1 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
MA30296B1 (fr) Nouvelles amines
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99007A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
Feng et al. In situ antibiofilm effect of glass-ionomer cement containing dimethylaminododecyl methacrylate